Table 1 Clinical and demographic features of study population, and comparison between MIDASRes / NON-MIDASRes and MMDRes / NON-MMDRes groups
Total | MIDASRes | NON-MIDASRes | p-value | MMDRes | NON-MMDRes | p-value | |
|---|---|---|---|---|---|---|---|
n | 77 | 43 | 34 | - | 42 | 35 | - |
Age, (years, m ± sd) | 49.8 ± 9.5 | 50.3 ± 9.1 | 49.2 ± 10.0 | 0.597 | 50.0 ± 9.1 | 49.2 ± 10.0 | 0.967 |
Females, n (%) | 55 (71.4) | 32 (74.4) | 23 (67.6) | 0.614 | 31 (73.8) | 24 (68.6) | 0.623 |
Age at headache onset (years, m ± sd) | 14.5 ± 6.9 | 13.2 ± 5.5 | 16.2 ± 8.1 | 0.104 | 15.2 ± 7.3 | 16.2 ± 8.1 | 0.300 |
Years lived with migraine (years, m ± sd) | 35.6 ± 10.8 | 37.1 ± 9.6 | 33.6 ± 11.9 | 0.177 | 35.3 ± 11.0 | 33.6 ± 11.9 | 0.701 |
Years lived with chronic migraine (years, m ± sd) | 13.1 ± 10.3 | 13.7 ± 10.3 | 12.4 ± 10.3 | 0.495 | 12.0 ± 9.3 | 12.4 ± 10.3 | 0.424 |
Migraine with aura, n (%) | 13 (16.9) | 6 (14.0) | 7 (20.6) | 0.545 | 8 (19.0) | 5 (14.3) | 0.762 |
MOH, n (%) | 71 (92.2) | 41 (95.3) | 30 (88.2) | 0.397 | 39 (92.9) | 32 (91.4) | 0.654 |
Previous detoxification for MOH, n (%) | 69 (89.6) | 40 (93.0) | 29 (85.3) | 38 (90.5) | 32 (91.4) | 0.652 | |
Preventive treatment | |||||||
Patients on preventive treatment at T0, n (%) | 42 (54.5) | 18 (41.9) | 24 (70.6) | 0.021 | 24 (57.1) | 18 (51.4) | 0.652 |
Number of previously failed preventive treatments (m ± sd) | 3.8 ± 1.2 | 4.0 ± 1.3 | 3.6 ± 1.5 | 0.199 | 3.8 ± 1.6 | 4.1 ± 0.98 | 0.439 |
Previous BoNT-A treatment, n (%) | 47 (61.0) | 27 (62.8) | 20 (58.8) | 0.815 | 24 (57.1) | 23 (65.7) | 0.488 |
Classes of acute drugs | |||||||
NSAIDs, n (%) | 12 (15.6) | 8 (18.6) | 4 (11.8) | 0.809 | 7 (16.7) | 5 (14.3) | 0.457 |
Triptans, n (%) | 20 (26.0) | 9 (20.9) | 11 (32.4) | 9 (21.4) | 11 (31.4) | ||
Combination, n (%) | 4 (5.2) | 3 (7.0) | 1 (2.9) | 1 (2.4) | 16 (45.7) | ||
Multiple drug classes, n (%) | 41 (53.2) | 23 (53.5) | 18 (52.9) | 25 (59.5) | 3 (8.57) | ||
Comorbidities | |||||||
Hypertension, n (%) | 19 (24.7) | 9 (20.9) | 10 (29.4) | 0.434 | 11 (26.2) | 8 (22.9) | 0.795 |
Anxiety, n (%) | 22 (28.6) | 13 (30.2) | 9 (26.5) | 0.916 | 12 (28.6) | 10 (28.6) | 0.999 |
Depression, n (%) | 4 (5.2) | 3 (7.0) | 1 (2.9) | 2 (4.8) | 2 (5.7) | ||
Anxiety and depression, n (%) | 18 (23.4) | 9 (20.9) | 9 (26.5) | 10 (23.8) | 8 (22.9) | ||
Insomnia, n (%) | 33 (42.9) | 18 (41.9) | 15 (44.1) | 0.842 | 18 (42.9) | 15 (42.9) | 1.000 |
Migraine features at baseline | |||||||
Monthly headache days (m ± sd) | 24.6 ± 4.8 | 25.3 ± 4.2 | 23.7 ± 5.4 | 0.281 | 24.5 ± 4.4 | 23.7 ± 5.4 | 0.545 |
Monthly migraine days (m ± sd) | 23.0 ± 5.1 | 23.7 ± 4.8 | 22.0 ± 5.3 | 0.172 | 23.2 ± 4.5 | 22.0 ± 5.3 | 0.861 |
Monthly days of acute drugs intake (m ± sd) | 20.8 ± 7.6 | 22.8 ± 7.1 | 18.1 ± 7.5 | 0.005 | 21.5 ± 6.9 | 18.1 ± 7.5 | 0.534 |
Monthly doses of acute drugs intake (m ± sd) | 34.7 ± 29.9 | 39.9 ± 33.5 | 28.7 ± 23.5 | 0.045 | 33.4 ± 29.9 | 36.4 ± 31.6 | 0.662 |
Questionnaires at baseline | |||||||
MIDAS (m ± sd) | 77.5 ± 69.0 | 80.9 ± 74.1 | 73.2 ± 62.6 | 0.275 | 72.1 ± 71.8 | 73.2 ± 62.8 | 0.452 |
Mean headache intensity (m ± sd) | 8.0 ± 6.4 | 7.3 ± 1.3 | 9.0 ± 9.4 | 0.461 | 7.3 ± 1.2 | 9.0 ± 9.4 | 0.349 |
HIT-6 (m ± sd) | 66.8 ± 5.8 | 67.1 ± 5.3 | 66.5 ± 6.4 | 0.651 | 65.8 ± 5.7 | 66.5 ± 6.5 | 0.113 |
ASC-12 (allodynia) (m ± sd) | 6.4 ± 5.1 | 5.9 ± 5.4 | 6.9 ± 4.8 | 0.264 | 6.2 ± 5.2 | 6.9 ± 4.8 | 0.707 |
MSQ (m ± sd) | 34.4 ± 18.1 | 38.1 ± 15.4 | 30.0 ± 20.3 | 0.068 | 37.4 ± 14.3 | 29.6 ± 20.3 | 0.190 |
General Health (0–100) (m ± sd) | 54.4 ± 22.3 | 54.2 ± 22.8 | 54.7 ± 21.9 | 0.869 | 61.5 ± 16.6 | 54.7 ± 22.0 | 0.002 |
HADS-A (m ± sd) | 6.51 ± 4.03 | 6.1 ± 3.7 | 7.0 ± 4.4 | 0.437 | 5.7 ± 3.6 | 7.0 ± 4.4 | 0.079 |
HADS-D (m ± sd) | 6.39 ± 4.40 | 6.0 ± 5.0 | 6.9 ± 4.3 | 0.255 | 5.4 ± 3.7 | 6.9 ± 4.3 | 0.035 |